Capital Insight Partners LLC Raises Position in Edwards Lifesciences Corp (EW)

Capital Insight Partners LLC lifted its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 0.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,010 shares of the medical research company’s stock after purchasing an additional 53 shares during the period. Edwards Lifesciences accounts for about 1.9% of Capital Insight Partners LLC’s portfolio, making the stock its 17th biggest position. Capital Insight Partners LLC’s holdings in Edwards Lifesciences were worth $2,107,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Standard Life Aberdeen plc boosted its position in shares of Edwards Lifesciences by 8.7% in the third quarter. Standard Life Aberdeen plc now owns 81,459 shares of the medical research company’s stock valued at $14,184,000 after acquiring an additional 6,529 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Edwards Lifesciences by 65.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 19,768 shares of the medical research company’s stock valued at $3,428,000 after purchasing an additional 7,792 shares in the last quarter. People s United Financial Inc. raised its stake in Edwards Lifesciences by 619.2% during the third quarter. People s United Financial Inc. now owns 35,642 shares of the medical research company’s stock worth $6,192,000 after acquiring an additional 30,686 shares in the last quarter. Partner Fund Management L.P. raised its stake in Edwards Lifesciences by 3.9% during the third quarter. Partner Fund Management L.P. now owns 522,672 shares of the medical research company’s stock worth $90,997,000 after acquiring an additional 19,427 shares in the last quarter. Finally, Lido Advisors LLC acquired a new position in Edwards Lifesciences during the third quarter worth $253,000. Institutional investors own 84.89% of the company’s stock.

NYSE:EW traded down $1.10 during trading hours on Friday, reaching $176.12. The stock had a trading volume of 1,265,412 shares, compared to its average volume of 1,340,253. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.61 and a quick ratio of 1.92. Edwards Lifesciences Corp has a 12-month low of $127.29 and a 12-month high of $197.86. The company has a market capitalization of $37.65 billion, a P/E ratio of 37.47, a P/E/G ratio of 2.35 and a beta of 0.91.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a return on equity of 31.71% and a net margin of 20.03%. The business had revenue of $993.00 million during the quarter, compared to the consensus estimate of $989.87 million. During the same period last year, the business posted $1.22 earnings per share. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. As a group, analysts anticipate that Edwards Lifesciences Corp will post 5.22 earnings per share for the current year.

EW has been the topic of several recent research reports. Credit Suisse Group raised their price target on Edwards Lifesciences from $189.00 to $221.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Raymond James cut their price objective on Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $180.00 to $190.00 in a research report on Friday, January 18th. Deutsche Bank began coverage on Edwards Lifesciences in a research report on Wednesday, January 2nd. They issued a “hold” rating and a $164.00 target price on the stock. Finally, Stifel Nicolaus lifted their target price on Edwards Lifesciences from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $187.19.

In other news, VP Robert W.A. Sellers sold 821 shares of Edwards Lifesciences stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $175.36, for a total value of $143,970.56. Following the transaction, the vice president now owns 14,176 shares in the company, valued at $2,485,903.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Catherine M. Szyman sold 1,474 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $192.00, for a total value of $283,008.00. Following the completion of the transaction, the vice president now directly owns 21,132 shares in the company, valued at $4,057,344. The disclosure for this sale can be found here. Insiders sold 115,149 shares of company stock valued at $20,265,275 over the last ninety days. Corporate insiders own 1.63% of the company’s stock.

WARNING: “Capital Insight Partners LLC Raises Position in Edwards Lifesciences Corp (EW)” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/edwards-lifesciences-corp-ew-holdings-boosted-by-capital-insight-partners-llc.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: Dollar Cost Averaging

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.